Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
Adia Med's CEO Larry Powalisz purchased a 7% economic interest in subsidiary Adia Labs for $350,000 in cash, buying seven membership units at $50,000 each. The per-unit price matches the company's recent sale of a 30% stake in Adia Labs to Live Oak Health LLC (QCM Biologics), and the deal was approved by independent directors with Live Oak's consent. Adia Med retains a majority economic interest, though Live Oak holds an option to acquire additional units. Powalisz framed the purchase as a personal vote of confidence in the business.
Key figures
- Price per unit
- $50,000
- Units purchased
- 7
- Related prior sale
- 30% of Adia Labs to Live Oak Health LLC at same per-unit price
- Subsidiary interest sold
- 7%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.